Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A.

Clin Cancer Res. 2019 Apr 1;25(7):2096-2108. doi: 10.1158/1078-0432.CCR-18-3496. Epub 2018 Dec 20.

PMID:
30573690
2.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT.

Clin Cancer Res. 2018 Nov 1;24(21):5347-5356. doi: 10.1158/1078-0432.CCR-18-1116. Epub 2018 Jun 13.

3.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.

Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B.

J Immunother. 2018 Jun;41(5):248-259. doi: 10.1097/CJI.0000000000000216.

4.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

5.

Mechanisms of Resistance to PD-1 and PD-L1 Blockade.

Nowicki TS, Hu-Lieskovan S, Ribas A.

Cancer J. 2018 Jan/Feb;24(1):47-53. doi: 10.1097/PPO.0000000000000303. Review.

6.

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Nowicki TS, Akiyama R, Huang RR, Shintaku IP, Wang X, Tumeh PC, Singh A, Chmielowski B, Denny C, Federman N, Ribas A.

Cancer Immunol Res. 2017 Feb;5(2):118-126. doi: 10.1158/2326-6066.CIR-16-0148. Epub 2016 Dec 30.

7.

Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.

Nowicki TS, Anderson JL, Federman N.

Pediatr Res. 2016 Mar;79(3):371-7. doi: 10.1038/pr.2015.246. Epub 2015 Nov 23. Review.

PMID:
26595537
8.

Acquired thrombotic thrombocytopenic purpura in children: a single institution experience.

Jayabose S, Nowicki TS, Dunbar J, Levendoglu-Tugal O, Ozkaynak MF, Sandoval C.

Indian J Pediatr. 2013 Jul;80(7):570-5. doi: 10.1007/s12098-012-0940-4. Epub 2012 Dec 21.

PMID:
23263974
9.

Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction.

Kummer NT, Nowicki TS, Azzi JP, Reyes I, Iacob C, Xie S, Swati I, Darzynkiewicz Z, Gotlinger KH, Suslina N, Schantz S, Tiwari RK, Geliebter J.

J Cell Biochem. 2012 Jun;113(6):1998-2008. doi: 10.1002/jcb.24069.

10.

The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.

Nowicki TS, Moscatello AL, Shin E, Schantz S, Tiwari RK, Geliebter J.

J Clin Endocrinol Metab. 2011 Oct;96(10):3062-4. doi: 10.1210/jc.2011-1123. Epub 2011 Aug 10. No abstract available.

11.

Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.

Nowicki TS, Zhao H, Darzynkiewicz Z, Moscatello A, Shin E, Schantz S, Tiwari RK, Geliebter J.

Cell Cycle. 2011 Jan 1;10(1):100-7. Epub 2011 Jan 1.

12.

Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells.

Nowicki TS, Kummer NT, Iacob C, Suslina N, Schaefer S, Schantz S, Shin E, Moscatello AL, Tiwari RK, Geliebter J.

Laryngoscope. 2010 Jul;120(7):1383-90. doi: 10.1002/lary.20915.

PMID:
20578104
13.

Automated analysis of protein subcellular location in time series images.

Hu Y, Osuna-Highley E, Hua J, Nowicki TS, Stolz R, McKayle C, Murphy RF.

Bioinformatics. 2010 Jul 1;26(13):1630-6. doi: 10.1093/bioinformatics/btq239. Epub 2010 May 19.

14.

Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.

Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C.

Pediatr Hematol Oncol. 2011 Mar;28(2):167-72. doi: 10.3109/08880011003739414. Epub 2010 May 14.

PMID:
20469972
15.

Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.

Nowicki TS, Bjornard K, Kudlowitz D, Sandoval C, Jayabose S.

J Pediatr Hematol Oncol. 2008 Dec;30(12):950-2. doi: 10.1097/MPH.0b013e318182e73e.

PMID:
19131789

Supplemental Content

Loading ...
Support Center